BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)

Phase 2 Completed 12 enrolled University of Heidelberg Medical Center Array BioPharma · collab Coordinating Centre for Clinical Trials Heidelberg · collab German Cancer Research Center · collab University Hospital Heidelberg · collab

NaSingle-groupOpen-labelTreatment

Summary

Trial for patients with refractory multiple myeloma after failure of at least two treatment regimens and with BRAFV600E/K Mutation to evaluate the efficacy of the kinase inhibitors Encorafenib (LGX818 in) combination with Binimetinib (MEK162).

Timeline

Start: 2016-06
Primary completion: 2023-03-29
Completion: 2023-03-29

Publications

Giesen N, Chatterjee M, Scheid C, Poos AM, Besemer B, Miah K, Benner A, Becker N, Moehler T, Metzler I, Khandanpour C, Seidel-Glaetzer A, Trautmann-Grill K, Kortum KM, Muller-Tidow C, Mechtersheimer G, Goeppert B, Stenzinger A, Weinhold N, Goldschmidt H, Weisel K, Raab MS. A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma. Blood. 2023 Apr 6;141(14):1685-1690. doi: 10.1182/blood.2022017789.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Binimetinib	Small molecule	45 mg	Oral
Subject	Encorafenib	Small molecule	450 mg	Oral

BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)

Summary

Timeline

Publications

Drugs

Indications